IL-17 Inhibitors vs. Methotrexate in Preventing New-Onset Psoriatic Arthritis in Psoriasis Patients: A Retrospective Population-Level Analysis

    July 2025 in “ Journal of Investigative Dermatology ”
    R.V. Paul Chan, Md. Rashedul Islam, Alexander Maltese, Kazi N. Islam, Jashin J. Wu
    TLDR IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.
    This study analyzed the effectiveness of IL-17 inhibitors (IL-17i) compared to methotrexate (MTX) in preventing new-onset psoriatic arthritis (PsA) in psoriasis patients. Using a 1:1 propensity score matched cohort of 8,531 patients each, the study found that IL-17i provided a protective effect against PsA, with a lower incidence rate (6.1%) compared to MTX (7.2%) and higher PsA-free survival (72.82% vs. 61.15%). The hazard ratio confirmed IL-17i's protective effect, suggesting it as a promising first-line therapy for psoriasis patients at risk of PsA. Further studies are recommended to assess long-term benefits.
    Discuss this study in the Community →